GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Insight Molecular Diagnostics Inc (NAS:IMDX) » Definitions » ROE %

IMDX (Insight Molecular Diagnostics) ROE % : 0.00% (As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is Insight Molecular Diagnostics ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Insight Molecular Diagnostics's annualized net income for the quarter that ended in Mar. 2025 was $-26.68 Mil. Insight Molecular Diagnostics's average Total Stockholders Equity over the quarter that ended in Mar. 2025 was $-1.03 Mil. Therefore, Insight Molecular Diagnostics's annualized ROE % for the quarter that ended in Mar. 2025 was N/A%.

The historical rank and industry rank for Insight Molecular Diagnostics's ROE % or its related term are showing as below:

IMDX' s ROE % Range Over the Past 10 Years
Min: -1480.67   Med: -138.72   Max: -93.07
Current: -693.81

During the past 12 years, Insight Molecular Diagnostics's highest ROE % was -93.07%. The lowest was -1,480.67%. And the median was -138.72%.

IMDX's ROE % is ranked worse than
100% of 204 companies
in the Medical Diagnostics & Research industry
Industry Median: -3.085 vs IMDX: -693.81

Insight Molecular Diagnostics ROE % Historical Data

The historical data trend for Insight Molecular Diagnostics's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Insight Molecular Diagnostics ROE % Chart

Insight Molecular Diagnostics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -93.07 -129.88 -146.52 -101.46 -1,480.67

Insight Molecular Diagnostics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -227.83 -105.68 -333.02 - -

Competitive Comparison of Insight Molecular Diagnostics's ROE %

For the Diagnostics & Research subindustry, Insight Molecular Diagnostics's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Insight Molecular Diagnostics's ROE % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Insight Molecular Diagnostics's ROE % distribution charts can be found below:

* The bar in red indicates where Insight Molecular Diagnostics's ROE % falls into.


;
;

Insight Molecular Diagnostics ROE % Calculation

Insight Molecular Diagnostics's annualized ROE % for the fiscal year that ended in Dec. 2024 is calculated as

ROE %=Net Income (A: Dec. 2024 )/( (Total Stockholders Equity (A: Dec. 2023 )+Total Stockholders Equity (A: Dec. 2024 ))/ count )
=-60.663/( (20.468+-12.274)/ 2 )
=-60.663/4.097
=-1,480.67 %

Insight Molecular Diagnostics's annualized ROE % for the quarter that ended in Mar. 2025 is calculated as

ROE %=Net Income (Q: Mar. 2025 )/( (Total Stockholders Equity (Q: Dec. 2024 )+Total Stockholders Equity (Q: Mar. 2025 ))/ count )
=-26.684/( (-12.274+10.218)/ 2 )
=-26.684/-1.028
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2025) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.


Insight Molecular Diagnostics  (NAS:IMDX) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2025 )
=Net Income/Total Stockholders Equity
=-26.684/-1.028
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-26.684 / 8.552)*(8.552 / 47.7205)*(47.7205 / -1.028)
=Net Margin %*Asset Turnover*Equity Multiplier
=-312.02 %*0.1792*N/A
=ROA %*Equity Multiplier
=-55.91 %*N/A
=N/A %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2025 )
=Net Income/Total Stockholders Equity
=-26.684/-1.028
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-26.684 / -26.684) * (-26.684 / -23.68) * (-23.68 / 8.552) * (8.552 / 47.7205) * (47.7205 / -1.028)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 1.1269 * -276.89 % * 0.1792 * N/A
=N/A %

Note: The net income data used here is four times the quarterly (Mar. 2025) net income data. The Revenue data used here is four times the quarterly (Mar. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Insight Molecular Diagnostics ROE % Related Terms

Thank you for viewing the detailed overview of Insight Molecular Diagnostics's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Insight Molecular Diagnostics Business Description

Traded in Other Exchanges
Address
15 Cushing, Irvine, CA, USA, 92618
OncoCyte Corp is a pioneering diagnostics technology company. Its mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers, or payers.
Executives
Broadwood Partners Lp 10 percent owner BROADWOOD CAPITAL INC., 142 WEST 57TH STREET, 11TH FLOOR, NEW YORK NY 10019
Andrew Arno director C/O MERRIMAN CURHAN FORD GROUP, INC., 600 CALIFORNIA STREET, 9TH FLOOR, SAN FRANCISCO CA 94108
Josh Riggs officer: Interim CEO 15 CUSHING, IRVINE CA 92618
John Peter Gutfreund other: Former Director 767 5TH AVENUE, 44TH FLOOR, NEW YORK NY 10153
Alfred D Kingsley director 150 E 57TH STREET, NEW YORK NY 10022
Pura Vida Investments, Llc 10 percent owner 512 W 22ND STREET, 7TH FLOOR, NEW YORK NY 10011
Lou Silverman director
James Yang Liu officer: Controller, PAO C/O ONCOCYTE CORPORATION, 15 CUSHING, IRVINE CA 92618
Andrew J. Last director 3420 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051
Jennifer L. Carter director C/O DFP SPONSOR LLC, 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Ronald Asbury Andrews director 5791 VAN ALLEN WAY, CARLSBAD CA 92008
Melinda Griffith director 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Anish M. John officer: SVP, Finance, and Interim CFO C/O ONCOCYTE CORPORATION,, 15 CUSHING, IRVINE CA 92618
Li Yu officer: VP Cntrllr/Prncpl Acctng Offcr 120 NEWPORT CENTER DRIVE., NEWPORT BEACH CA 92660
Efrem Kamen 10 percent owner C/O PURA VIDA INVESTMENTS, LLC, 512 W 22ND STREET, 7TH FLOOR, NEW YORK NY 10011